FibroGen (NASDAQ:FGEN) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Several other equities research analysts also recently issued reports on FGEN. Stifel Nicolaus increased their price objective on FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Jefferies Group reissued a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research note on Tuesday, August 8th. Citigroup increased their price objective on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. Leerink Swann reissued an “outperform” rating and issued a $82.00 price objective (up from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. Finally, William Blair reissued an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $65.67.

FibroGen (FGEN) opened at $47.15 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83. FibroGen has a 1 year low of $19.25 and a 1 year high of $60.15.

In other news, VP Pat Cotroneo sold 2,851 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $49.45, for a total transaction of $140,981.95. Following the completion of the sale, the vice president now directly owns 157,405 shares of the company’s stock, valued at approximately $7,783,677.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $52.24, for a total value of $104,480.00. Following the sale, the director now directly owns 26,000 shares of the company’s stock, valued at $1,358,240. The disclosure for this sale can be found here. Over the last three months, insiders sold 387,982 shares of company stock valued at $20,683,362. Company insiders own 13.60% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of FibroGen by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after purchasing an additional 761,421 shares in the last quarter. BlackRock Inc. raised its stake in shares of FibroGen by 12.3% during the 2nd quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock worth $161,545,000 after purchasing an additional 546,587 shares in the last quarter. FMR LLC raised its stake in shares of FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after purchasing an additional 1,641,423 shares in the last quarter. State Street Corp raised its stake in shares of FibroGen by 16.4% during the 2nd quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock worth $56,962,000 after purchasing an additional 248,922 shares in the last quarter. Finally, Hillhouse Capital Management Ltd. raised its stake in shares of FibroGen by 75.0% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $56,525,000 after purchasing an additional 750,000 shares in the last quarter. 57.42% of the stock is owned by institutional investors.

WARNING: “FibroGen (FGEN) Downgraded by ValuEngine” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/02/fibrogen-fgen-downgraded-by-valuengine.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.